Mobile app version of munafa.us
Login or Join
 Learn then Earn
stockMarketNEWS

 story : : Takeda inks deal with Hutchmed for up to .1 billion #FinanceUSA #StockMarketNEWS Takeda Pharmaceutical Co. Ltd. TAKJP:4502 said Monday that it will acquire Hutchmed’s HCMHK:13 experimental cancer

@stockMarketNEWS 11 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

: Takeda inks deal with Hutchmed for up to .1 billion #FinanceUSA #StockMarketNEWS
Takeda Pharmaceutical Co. Ltd. TAKJP:4502 said Monday that it will acquire Hutchmed’s HCMHK:13 experimental cancer treatment outside mainland China, Hong Kong and Macau, with plans to develop and commercialize fruquintinib. Per the terms of the deal, Takeda will make an upfront payment to Hutchmed for 0 million, with up to 0 million in potential milestone and royalty payments. The drug, fruquintinib, is approved in China as a treatment for refractory metastatic colorectal cancer. It is currently under review at the Food and Drug Administration. U.S.-listed shares of Takeda are up about 11% over the past year, while the S&P 500 SPX has declined 9.7%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme